Small molecule inhibitor and application thereof in inhibition of S-adenosylmethionine decarboxylase

By developing new small molecule inhibitors, the existing AdoMetDC inhibitors have poor mitochondrial toxicity and effects have been solved, and effective inhibition of AdoMetDC and killing effects on tumor cells have been achieved, with great therapeutic prospects.

CN119055641APending Publication Date: 2024-12-03HUBEI UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310649733.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing S-adenosylmethionine decarboxylase (AdoMetDC) inhibitors such as MGBG have mitochondrial toxicity and their effect on polyamines is not ideal, making it difficult to effectively treat a variety of malignant diseases.

Method used

Develop a new small molecule inhibitor, which is used to construct AdoMetDC protein plasmid and express and purify, and is used to purify it by combining Ni-NTA His tag protein binding filler to detect its inhibitory activity, and detect T47D at different concentrations of small molecules Cell killing effect.

Benefits of technology

This small molecule inhibitor shows good AdoMetDC inhibition effect, has great application prospects, and can effectively treat diseases such as acute leukemia, lymphoma and multiple myeloma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055641A_ABST
    Figure CN119055641A_ABST
Patent Text Reader

Abstract

The invention discloses a small molecule inhibitor of S-adenosylmethionine decarboxylase (AdoMetDC) and application of the small molecule inhibitor of the S-adenosylmethionine decarboxylase (AdoMetDC). According to verification, the novel small-molecule inhibitor aiming at S-adenosylmethionine decarboxylase (AdoMetDC) provided by the invention has a good inhibition effect on AdoMetDC, can be particularly used for inhibiting human AdoMetDC, and has the advantages of prevention and treatment of tumor diseases, pathogenic microorganism infection, pathogenic bacterium infection and the like. The method has great application potential in the fields of research, development and preparation of tumor drugs or pathogenic microorganism infection drugs and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to a small molecule inhibitor of S-adenosylmethionine decarboxylase (AdoMetDC) and an application thereof; in particular, it relates to a small molecule inhibitor of human S-adenosylmethionine decarboxylase and an application thereof in inhibiting and killing tumor cells. Background Art

[0002] Protein is the material basis of all life and an important component of body cells. Enzymes, as an important form of protein, play an important role in life activities. Enzymes have high specificity and catalytic efficiency for substrates and regulate almost all biochemical reaction processes in organisms. The activity of enzymes is strictly regulated in organisms. Once there is a problem with its regulatory mechanism, resulting in excessive, too low or complete inactivation of the enzyme activity, it will cause the occurrence of corresponding diseases. Therefore, it is of great theoretical and practical significance to regulate enzyme activity through drugs to restore and maintain it at normal levels. Structure-based drug design is an important means of discovering protein target drugs.

[0003] Polyamines are polycationic alkylamines, including putrescine, spermidine and spermine, which are present in mammalian cells at millimolar concentrations. Polyamine metabolism is closely related to many basic cellular processes, such as differentiation, apoptosis, nucleic acid synthesis, transcription, translation, autophagy and protection from oxidative stress. Under normal physiological conditions, the concentration of intracellular polyamines is strictly regulated by a dynamic network of biosynthetic and catabolic enzymes and transport systems. This precise regulation ensures that the concentration of intracellular polyamines remains within a strictly controlled range. Studies have found that rapid tumor growth depends on higher intracellular polyamine levels, so the metabolism of polyamines in tumors and the demand for polyamines are often dysregulated, including breast cancer, colon cancer, lung cancer, prostate cancer and skin cancer. In tumor cells, polyamines are directly involved in a variety of carcinogenic and cell signaling pathways. Data show that polyamine pathways are related to many oncogenes, such as downstream targets Myc and Ras, so especially in oncogene-driven cancers, the loss of growth control in cancer cells makes transformed cells more sensitive to polyamine depletion than normal cells. The polyamine metabolic pathway has become a reasonable target for chemoprevention and chemotherapy. In recent years, many polyamine biosynthesis inhibitors have been explored as cancer therapeutics, and the potential of utilizing polyamine metabolic pathways as cancer treatment and prevention strategies has gradually increased. Altering the regulation of rate-limiting enzymes in the polyamine pathway is a strategy to address various types of cancer.

[0004] As the rate-limiting enzyme in the polyamine pathway, S-adenosylmethionine decarboxylase (AdoMetDC) is a pyruvyl decarboxylase. AdoMetDC catalyzes the conversion of S-adenosylmethionine (AdoMet) into decarboxylated S-adenosylmethionine (dcAdoMet), while producing carbon dioxide. Decarboxylated S-adenosylmethionine transfers the aminopropyl group to spermidine synthetase and spermine synthetase. Putrescine and spermidine form spermidine and spermine, respectively, under the catalysis of spermidine synthetase and spermine synthetase, and are fully dedicated to the biosynthesis of polyamines. Therefore, the expression and activity of AdoMetDC are closely related to the cellular concentration of polyamines. In addition, S-adenosylmethionine is also the source of methyl groups for many methyl transfer reactions (such as histone and DNA methylation processes). Methyl transfer activity is related to S-adenosylmethionine-dependent methyltransferases. Changes in the activity of AdoMetDC enzymes will affect the function of S-adenosylmethionine in methyl transfer. The polyamine biosynthesis machinery is upregulated in many types of cancer and parasitic diseases, and S-adenosylmethionine decarboxylase, as the rate-limiting enzyme of the polyamine pathway, has become an attractive cancer drug target.

[0005] The inhibitor of AdoMetDC, methylglyoxal diguanylhydrazone (MGBG), is a structural analog of spermidine and has been shown to competitively inhibit AdoMetDC and reduce the intracellular levels of spermidine and spermine, while increasing the level of putrescine. MGBG is also the first AdoMetDC inhibitor to be extensively studied in preclinical and clinical studies. In clinical studies, MGBG has been shown to be effective in treating a variety of malignant diseases, including acute leukemia, lymphoma, and multiple myeloma. However, the mitochondrial toxicity shown by MGBG treatment precedes its effect on polyamines, so it is very necessary to develop new AdoMetDC inhibitors with better effects. Summary of the invention

[0006] In view of the above technical problems, the purpose of the present invention is to provide a new small molecule inhibitor against AdoMetDC, which can be applied to inhibitors of S-adenosylmethionine decarboxylase and may be used to prepare drugs for treating tumors and pathogenic microorganism infections.

[0007] The technical solution provided by the present invention is as follows:

[0008] In a first aspect, the present invention provides the use of a small molecule inhibitor in the preparation of a drug for inhibiting S-adenosylmethionine decarboxylase, and the structure of the small molecule is as follows:

[0009]

[0010]

[0011] Wherein, R is NH2-NH-.

[0012] Furthermore, the AdoMetDC protein is a human AdoMetDC protein.

[0013] Furthermore, the molar concentration ratio of the small molecule inhibitor in the final reaction volume is small molecule inhibitor: protein = 3: 1 to 100: 1. Preferably, the molar concentration ratio of the small molecule inhibitor in the final reaction volume is small molecule inhibitor: protein = 50: 1 to 100: 1.

[0014] In a second aspect, the present invention provides a method for using the above-mentioned small molecule to inhibit S-adenosylmethionine decarboxylase, the specific steps of which are as follows:

[0015] 1. Construction of AdoMetDC prokaryotic gene plasmid

[0016] The AdoMetDC gene sequence was inserted into the pET28a plasmid through the NcoⅠ and XXoⅠ restriction sites to construct the pET28a-His-AdoMetDC plasmid, which was verified by DNA sequencing;

[0017] 2. Expression of AdoMetDC protein

[0018] The pFET28a-His-AdoMetDC plasmid constructed in step 1 was transformed into the Escherichia coli BL21 strain by the CaCl2 method, and selected by ampicillin. Then, the strain grown on the Luria-Bertani (LB) culture plate containing ampicillin was inoculated into the LB liquid medium containing ampicillin for culture, and finally, the bacteria were collected by centrifugation;

[0019] 3. Purification of AdoMetDC protein

[0020] The bacterial sludge collected in step 2 is resuspended in a lysis buffer, lysed by ultrasonic method, and then the lysate is centrifuged to retain the supernatant; finally, the Ni-NTAHis tag protein is used to bind and purify the filler to obtain the AdoMetDC protein;

[0021] 4. Activity test of AdoMetDC protein

[0022] Add AdoMetDC and UP H2O to the B row of the well plate in two parallel groups and mix them well, then add carbon dioxide determination reagent R2; then add UP H2O, AdoMet, and carbon dioxide determination reagent R1 to row A. Incubate in a constant temperature oven, then use a spray gun to blow and mix well, then draw from well A and add to well B, and continuously detect activity.

[0023] 5. Detection of inhibitory activity against AdoMetDC protein

[0024] First, add AdoMetDC, UP H2O, DMSO or small molecules to the EP tube and mix them well, then incubate at a constant temperature, and then divide them into two parallel rows of the well plate in each group, and then add carbon dioxide determination reagent R2; then add UP H2O, AdoMet, and carbon dioxide determination reagent R1 to row A. Incubate in a constant temperature box, then blow and evenly use a spray gun to draw from well A and add to well B, and continuously detect activity.

[0025] The AdoMetDC inhibition rate was calculated by the following formula:

[0026] Control difference = the highest OD value during the test of the group without small molecule inhibitors - the OD value at 5 min of the group without small molecule inhibitors;

[0027] Experimental difference = the highest OD value during the test of the group with small molecule inhibitors - the OD value of the group with small molecule inhibitors at 5 minutes; AdoMetDC inhibition rate = [(control difference - experimental difference) / control difference] × 100%;

[0028] 6. MALDI-TOF covalent binding verification

[0029] AdoMetDC protein and small molecules are incubated in an incubation buffer for a certain period of time; SA and samples are spotted on a metal plate, and after complete evaporation, they are placed in an instrument for detection.

[0030] 7. CCK-8 assay to detect the killing effect of small molecules at different concentrations on T47D cells

[0031] Take T47D cells in the logarithmic growth phase, make a cell suspension after standard digestion treatment, count the cells to get the concentration of the cell suspension, inoculate them in a well plate at a certain density, and place them in a 37°C CO2 incubator for overnight adherent culture. The next day, discard the old culture medium in each well, treat the cells with culture medium containing different small molecules, and then place them in an incubator for incubation. After the drug incubation is completed, aspirate the old culture medium, and then add culture medium containing CCK-8 to each experimental well. Place in the incubator to continue incubation, and then use an enzyme-labeled detector to detect the absorbance value (OD value) of each well.

[0032] The cell viability of T47D was calculated by the following formula:

[0033] Calculate cell survival rate (%) = (OD drug-OD blank) / (OD control-OD blank) × 100%

[0034] Furthermore, the lysis buffer in step 3 is: 20 mM Na2HPO4·12H2O, 500 mM NaCl, 30 mM imidazole, 2.5 mM Put, pH 7.0.

[0035] Furthermore, the incubation buffer described in step 6 is: 100 mM NaCl, 20 mM Na2HPO4, pH 7.0.

[0036] According to the above scheme, small molecules with potential inhibitory activity were experimentally screened.

[0037] The beneficial effects of the present invention are as follows:

[0038] The present invention provides a small molecule inhibitor, which exhibits a good inhibitory effect on AdoMetDC and can be used to prepare AdoMetDC inhibitors and combination drugs to treat related diseases, such as acute leukemia, lymphoma and multiple myeloma, and has great application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 Flowchart for validation of relevant inhibitory effects;

[0040] Figure 2 This is the activity verification of the AdoMetDC protein in Example 1;

[0041] Figure 3 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 1; Figure 3 (Middle) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 1; Figure 3 (Right) shows the killing effect of different concentrations of small molecules on T47D cells in Example 1;

[0042] Figure 4 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 2; Figure 4 (Middle) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 2; Figure 4 (Right) shows the killing effect of 100 μM small molecule on T47D cells in Example 2;

[0043] Figure 5 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 3; Figure 5 (Middle) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 3; Figure 5 (Right) shows the killing effect of 100 μM small molecule on T47D cells in Example 3;

[0044] Figure 6 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 4; Figure 6 (Middle) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 4; Figure 6(Right) shows the killing effect of 100 μM small molecule on T47D cells in Example 4;

[0045] Figure 7 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 5; Figure 7 (Right) shows the killing effect of small molecules at different concentrations on T47D cells in Example 5;

[0046] Figure 8 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 6; Figure 8 (Right) shows the killing effect of different concentrations of small molecules on T47D cells in Example 8;

[0047] Fig. 9 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 7; Fig. 9 (Middle) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 7; Fig. 9 (Right) shows the killing effect of 100 μM small molecule on T47D cells in Example 7;

[0048] Fig.10 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 8; Fig.10 (Middle) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 8; Fig.10 (Right) shows the killing effect of different concentrations of small molecules on T47D cells in Example 8;

[0049] Fig.11 (Left) shows the inhibitory effects of different concentrations of small molecules on AdoMetDC protein in Example 9; Fig.11 (Right) shows the killing effect of 100 μM small molecule on T47D cells in Example 9;

[0050] Fig.12 (Left) shows the inhibitory effects of different concentrations of small molecules on AdoMetDC protein in Example 10; Fig.12 (Middle) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 10; Fig.12 (Right) shows the killing effect of 100 μM small molecule on T47D cells in Example 10;

[0051] Fig.13 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 11; Fig.13 (Middle) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 11; Fig.13 (Right) shows the killing effect of different concentrations of small molecules on T47D cells in Example 11;

[0052] Fig.14 (Left) shows the inhibitory effects of different concentrations of small molecules on AdoMetDC protein in Example 12; Fig.14 (Middle) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 12; Fig.14 (Right) shows the killing effect of small molecules at different concentrations on T47D cells in Example 12;

[0053] Fig.15 (Left) shows the inhibitory effects of different concentrations of small molecules on AdoMetDC protein in Example 13; Fig.15 (Middle) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 13; Fig.15 (Right) shows the killing effect of 100 μM small molecule on T47D cells in Example 13;

[0054] Fig.16 (Left) shows the inhibitory effects of different concentrations of small molecules on AdoMetDC protein in Example 14; Fig.16 (Middle) is a mass spectrum of the molecular weight of the protein after adding small molecules in Example 14; Fig.16 (Right) shows the killing effect of different concentrations of small molecules on T47D cells in Example 14;

[0055] Fig.17 (Left) shows the inhibitory effect of different concentrations of small molecules on AdoMetDC protein in Example 15; Fig.17 (Middle) is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 15; Fig.17 (Right) shows the killing effect of small molecules at different concentrations in Example 15 on T47D cells. DETAILED DESCRIPTION

[0056] The present invention is further described below in conjunction with specific embodiments, but the content of the present invention is not limited thereto at all.

[0057] Example 1

[0058] The small molecule inhibitor involved is: Compound 1, the structural formula is as follows:

[0059]

[0060] The activity detection method is as follows:

[0061] 1. Construction of AdoMetDC prokaryotic gene plasmid

[0062] The AdoMetDC gene sequence was inserted into the pET28a plasmid through the NcoⅠ and XXoⅠ restriction sites to construct the pET28a-His-AdoMetDC plasmid, which was verified by DNA sequencing;

[0063] Human AdoMetDC gene sequence:

[0064]

[0065] 2. Expression of AdoMetDC protein

[0066] The pFET28a-His-AdoMetDC plasmid constructed in step 1 was transformed into the Escherichia coli BL21 strain by the CaCl2 method, and selected by ampicillin. Then, the strain grown on the Luria-Bertani (LB) culture plate containing ampicillin was inoculated into the LB liquid medium containing ampicillin, and cultured at 37°C and 220rpm to the logarithmic growth phase, and then isopropylthiogalactoside (IPTG) was added to 0.5mM, and the expression was induced at 16°C for 12 hours. Finally, the bacteria were collected by centrifugation;

[0067] 3. Purification of AdoMetDC protein

[0068] The bacterial sludge collected in step 2 was resuspended with lysis buffer, lysed by ultrasonic method, and then the lysate was centrifuged at 4°C and 10000rpm / min, and the supernatant was retained; finally, Ni-NTA His tag protein binding filler was used for binding and purification to obtain AdoMetDC protein, and the elution buffer composition of AdoMetDC protein was: 20mMNa2HPO412H2O, 500mM NaCl, 400mM imidazole, 2.5mM Put, pH 7.0;

[0069] 4. Activity test of AdoMetDC protein

[0070] After AdoMetDC and UP H2O were added to the B row of the 96-well plate in parallel in each group and mixed, the carbon dioxide determination reagent R2 was added to make the volume of each well in row B 45μL, and then UP H2O, AdoMet, and carbon dioxide determination reagent R1 were added to row A for a total of 200μL. Incubate in a 37℃ constant temperature box for 5min to make the system temperature reach 37℃, then blow and evenly use a spray gun to draw 155μL from well A and add it to well B, and continuously detect at 37℃ and 340nm for 10min, with an interval of 30s each time.

[0071] The absorption spectrum obtained by the above method is as follows: Figure 2 As shown in the figure, it can be seen that the absorption light intensity reaches the maximum value and then begins to gradually decrease, thereby judging that the protein is active.

[0072] 5. Detection of inhibitory activity against AdoMetDC protein

[0073] First, add 3.3μL of 185μM AdoMetDC, 13.7μL of UP H2O, and 0.8μL of DMSO or small molecules to the EP tube and mix well, then incubate at 37℃ for 10min, then divide into two parallel groups in row B of the 96-well plate, add carbon dioxide determination reagent R2, so that the volume of each well in row B is 58μL, then add UP H2O, AdoMet, and carbon dioxide determination reagent R1 to row A for a total of 200μL. Incubate in a 37℃ constant temperature box for 5min to make the system temperature reach 37℃, then use a spray gun to blow evenly and draw 142μL from well A to well B, and continuously detect at 37℃ and 340nm for 10min, with an interval of 30s each time.

[0074] The AdoMetDC inhibition rate was calculated by the following formula:

[0075] Control difference = the highest OD value during the test of the group without small molecule inhibitors - the OD value at 5 min of the group without small molecule inhibitors;

[0076] Experimental difference = the highest OD value during the test of the group with small molecule inhibitors - the OD value of the group with small molecule inhibitors at 5 minutes; AdoMetDC inhibition rate = [(control difference - experimental difference) / control difference] × 100%;

[0077] The inhibitory effect of the small molecule inhibitor obtained by the above method is as follows Figure 3 As shown in (left), it can be seen from the figure that from 1μM to 100μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0078] 6. MALDI-TOF covalent binding verification

[0079] The AdoMetDC protein and small molecules were incubated in an incubation buffer at 37°C for a certain period of time; 1 μL of matrix SA (sinapic acid solution) and 1 μL of sample were spotted on a metal plate, and after complete evaporation, they were placed in an instrument for detection.

[0080] The mass spectrum obtained by the above method is as follows: Figure 3 (Middle) As can be seen from the figure, the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0081] 7. CCK-8 assay to detect the killing effect of small molecules at different concentrations on T47D cells

[0082] Take T47D cells in the logarithmic growth phase, make a cell suspension after standard digestion treatment, count the cells to get the concentration of the cell suspension, inoculate in a 96-well plate at a density of 3000 cells / well, and place the cell suspension in each well at 37°C in a 5% CO2 incubator overnight. The next day, discard the old culture medium in each well, treat the cells with a culture medium containing 100μM of different small molecules, and then place them in an incubator for 72X incubation. After the drug incubation is completed, aspirate the old culture medium, and then add 100μL of culture medium containing 5% CCK-8 to each experimental well. Place in an incubator and continue incubation for 2X, then use an enzyme-labeled detector to detect the absorbance value (OD value) of each well, and the measurement wavelength is 450nm.

[0083] The cell viability of T47D was calculated by the following formula:

[0084] Calculate cell survival rate (%) = (OD drug-OD blank) / (OD control-OD blank) × 100%

[0085] According to the above method, the killing effect of the small molecule on T47D cells was obtained, such as Figure 3 As shown in (right), it can be seen from the figure that from 1μM to 100μM, as the concentration of small molecules continues to increase, the killing effect gradually increases.

[0086] Example 2

[0087] The small molecule inhibitor involved is: Compound 2, the structure of which is shown below:

[0088]

[0089] The activity detection method is the same as in Example 1.

[0090] The results are as follows:

[0091] Figure 4 (Left) It can be seen that from 1 μM to 200 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0092] Figure 4 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0093] Figure 4 (Right) It can be seen that the small molecule concentration is 100 μM, which has a certain killing effect.

[0094] Example 3

[0095] The small molecule inhibitor involved is: Compound 3, the structure of which is shown below:

[0096]

[0097] The activity detection method is the same as in Example 1.

[0098] The results are as follows:

[0099] Figure 5 (Left) It can be seen that from 1 μM to 200 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0100] Figure 5 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0101] Figure 5 (Right) It can be seen that the small molecule concentration is 100 μM, which has a certain killing effect.

[0102] Example 4

[0103] The small molecule inhibitor involved is: Compound 4, the structure of which is shown below:

[0104]

[0105] The activity detection method is the same as in Example 1.

[0106] The results are as follows:

[0107] Figure 6 (Left) It can be seen that from 1 μM to 400 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0108] Figure 6 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0109] Figure 6 (Right) It can be seen that the small molecule concentration is 50 μM, which has a certain killing effect.

[0110] Example 5

[0111] The small molecule inhibitor involved is: Compound 5, the structure of which is shown below:

[0112]

[0113] The activity detection method is the same as in Example 1.

[0114] The results are as follows:

[0115] Figure 7(Left) It can be seen that from 1 μM to 400 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0116] Figure 7 (Right) It can be seen that from 1 μM to 100 μM, as the concentration of small molecules continues to increase, the killing effect gradually increases.

[0117] Example 6

[0118] The small molecule inhibitor involved is: Compound 6, the structure of which is shown below:

[0119]

[0120] The activity detection method is the same as in Example 1.

[0121] The results are as follows:

[0122] Figure 8 (Left) It can be seen that from 1 μM to 50 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0123] Figure 8 (Right) It can be seen that from 1 μM to 100 μM, as the concentration of small molecules continues to increase, the killing effect gradually increases.

[0124] Example 7

[0125] The small molecule inhibitor involved is: Compound 7, the structure of which is shown below:

[0126]

[0127] The activity detection method is the same as in Example 1.

[0128] The results are as follows:

[0129] Fig. 9 (Left) It can be seen that from 1 μM to 400 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0130] Fig. 9 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0131] Fig. 9 (Right) It can be seen that the small molecule concentration is 100 μM, which has a certain killing effect.

[0132] Example 8

[0133] The small molecule inhibitor involved is: Compound 8, the structure of which is shown below:

[0134]

[0135] The activity detection method is the same as in Example 1.

[0136] The results are as follows:

[0137] Fig.10 (Left) It can be seen that from 1 μM to 400 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0138] Fig.10 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0139] Fig.10 (Right) It can be seen that from 1 μM to 100 μM, as the concentration of small molecules continues to increase, the killing effect gradually increases.

[0140] Example 9

[0141] The small molecule inhibitor involved is: Compound 9, the structure of which is shown below:

[0142]

[0143] The activity detection method is the same as in Example 1.

[0144] The results are as follows:

[0145] Fig.11 (Left) It can be seen that from 1 μM to 400 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0146] Fig.11 (Right) It can be seen that the small molecule concentration is 100 μM, which has a certain killing effect.

[0147] Example 10

[0148] The small molecule inhibitor involved is: Compound 10, the structure of which is shown below:

[0149]

[0150] The activity detection method is the same as in Example 1.

[0151] The results are as follows:

[0152] Fig.12 (Left) It can be seen that from 1 μM to 400 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0153] Fig.12 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0154] Fig.12 (Right) It can be seen that the small molecule concentration is 100 μM, which has a certain killing effect.

[0155] Embodiment 11

[0156] The small molecule inhibitor involved is: Compound 11, the structure of which is shown below:

[0157]

[0158] The activity detection method is the same as in Example 1.

[0159] The results are as follows:

[0160] Fig.13 (Left) It can be seen that from 1 μM to 100 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0161] Fig.13 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0162] Fig.13 (Right) It can be seen that from 1 μM to 100 μM, as the concentration of small molecules continues to increase, the killing effect gradually increases.

[0163] Example 12

[0164] The small molecule inhibitor involved is: Compound 12, the structure of which is shown below:

[0165]

[0166] The activity detection method is the same as in Example 1.

[0167] The results are as follows:

[0168] Fig.14 (Left) It can be seen that from 1 μM to 400 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0169] Fig.14 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0170] Fig.14 (Right) It can be seen that from 1 μM to 100 μM, as the concentration of small molecules continues to increase, the killing effect gradually increases.

[0171] Example 13

[0172] The small molecule inhibitor involved is: Compound 13, the structure of which is shown below:

[0173]

[0174] The activity detection method is the same as in Example 1.

[0175] The results are as follows:

[0176] Fig.15 (Left) It can be seen that from 1 μM to 400 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0177] Fig.15 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules did not change relative to the protein group.

[0178] Fig.15 (Right) It can be seen that the small molecule concentration is 100 μM, which has a certain killing effect.

[0179] Embodiment 14

[0180] The small molecule inhibitor involved is: Compound 14, the structure of which is shown below:

[0181]

[0182] The activity detection method is the same as in Example 1.

[0183] The results are as follows:

[0184] Fig.16 (Left) It can be seen that from 1 μM to 400 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0185] Fig.16 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0186] Fig.16 (Right) It can be seen that from 1 μM to 100 μM, as the concentration of small molecules continues to increase, the killing effect gradually increases.

[0187] Embodiment 15

[0188] The small molecule inhibitor involved is: Compound 15, the structure of which is shown below:

[0189]

[0190] The activity detection method is the same as in Example 1.

[0191] The results are as follows:

[0192] Fig.17 (Left) It can be seen that from 1 μM to 200 μM, as the concentration of small molecules continues to increase, the inhibitory effect gradually increases.

[0193] Fig.17 (Middle) It can be seen that the molecular weight of the experimental group with the addition of small molecules has a large rightward shift relative to the protein group, which can be judged that the small molecules and proteins are covalently bound.

[0194] Fig.17 (Right) It can be seen that from 1μM to 250μM, as the concentration of small molecules continues to increase, the killing effect gradually increases.

[0195] The above description is only a preferred specific implementation manner of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention should be included in the scope of protection of the invention.

Claims

1. Application of small molecule inhibitors in the preparation of drugs that inhibit S-adenosylmethionine decarboxylase, Features: The structure of this small molecule is as follows: Where R is NH 2 -NH-.

2. Use of the small molecule inhibitor according to claim 1 in the preparation of drugs for inhibiting S-adenosylmethionine decarboxylase, Features: The S-adenosylmethionine decarboxylase is human S-adenosylmethionine decarboxylase.

3. Use of the small molecule inhibitor according to claim 1 in the preparation of drugs for inhibiting S-adenosylmethionine decarboxylase, Features: The molar concentration ratio of the small molecule inhibitor in the final reaction volume is in the range of small molecule inhibitor:protein=3:1-100:1.